The FDA has approved a new prescription drug called Steglatro (ertugliflozin) to help adults with type 2 diabetes manage their blood sugar. It is meant to be used together with a healthy diet and regular exercise. Steglatro belongs to a class of drugs known as SGLT2 inhibitors, which work by helping the kidneys remove extra sugar from the body through urine.
Steglatro is for adults with type 2 diabetes. It is not for people with type 1 diabetes. The typical starting dose is 5 mg once a day, taken with or without food. If needed, the dose can be increased to 15 mg. However, people with kidney problems (eGFR below 45) should not take this drug.
In clinical studies, Steglatro lowered blood sugar levels better than a placebo. Its side effects are similar to other SGLT2 inhibitors and may include urinary tract infections and dehydration. The approval gives patients and doctors another tool for managing diabetes.
If you have type 2 diabetes, talk to your doctor about whether Steglatro might be right for you. This approval does not mean you should stop your current treatment or change your diet without medical advice.